MedPath

Pilot Study: Post-Recovery LibEration From Oxygen in Exacerbated COPD

Not Applicable
Withdrawn
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Other: Rescind home oxygen order
Behavioral: Provider Education
Behavioral: Patient Education
Behavioral: Teach-to-goal inhaler training
Behavioral: Pursed lip breathing
Registration Number
NCT04854967
Lead Sponsor
VA Office of Research and Development
Brief Summary

The investigators want to decrease inappropriate oxygen use for patients with COPD. The investigators are testing a new program that will stop oxygen prescriptions for patients that no longer need it and will instead provide them with training in skills that have been shown to help patients breathe better. Participants will be randomly assigned to receive the intervention program or usual care. After 12 weeks the investigators will determine if the program helped stop unnecessary oxygen prescription. The investigators will also determine if health status, distance walked during six minutes, and symptoms of breathlessness after walking are different between participants who received the program and those who did not. The investigators will meet with participating patients and their providers after the study is complete to find out how they feel about this program and if it would be possible to put this change into practice.

Detailed Description

The purpose of this pilot study is to test an intervention designed to decrease inappropriate oxygen use for patients with COPD. Participants will be randomized to usual care vs. an oxygen de-implementation intervention. Patients assigned to the oxygen de-implementation intervention group will have their active oxygen prescription discontinued, be educated on pursed lip breathing and receive inhaler training. A follow-up assessment will occur at 12 weeks. The primary outcome at 12 weeks will be discontinuation of oxygen. Secondary outcomes include health status as measured by the Clinical COPD Questionnaire (CCQ), tele-six minute walk test (6MWT) distance, and Borg dyspnea scale assessed after the tele-6MWT. Among the intervention group, the investigators will also assess acceptability and feasibility of the intervention for patient participants and their providers.

Recruitment was expected to begin in November 2021 but was delayed due to the COVID-19 Omicron outbreak. Recruitment officially began on April 18, 2022.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Age 40 years or older
  • Diagnosis of COPD
  • Discharged within the past 3 months after hospitalization for COPD exacerbation, CHF exacerbation and/or Pneumonia and Active prescription for supplemental oxygen within 48 hours of discharge that remains active; or Stable COPD with no chronic resting hypoxemia and an active prescription for supplemental oxygen.
  • No inpatient or outpatient exacerbations of COPD within the last 30 days
  • Smoked at least 10 pack-years of cigarettes
  • Room air resting saturation >88% on room air
  • Spirometry consistent with COPD (FEV1/FVC < 0.70) and/or evidence of emphysema on CT scan
  • Willingness on the part of the participant to stop oxygen if randomized to the intervention
  • Ability and willingness to participate in virtual video visits with study staff using VA approved software
  • Informed consent for participation
Exclusion Criteria
  • Desaturation during 6MWT <80% for one minute or more
  • Non-COPD lung disease that affects oxygenation or survival (including pulmonary hypertension)
  • Prescription of oxygen for alternative condition (e.g. bleed-in with positive airway pressure therapy for obstructive sleep apnea)
  • Diagnosis expected to result in death in six months or enrollment in hospice
  • Participation in another intervention trial
  • Cognitive issues that would preclude participation (dementia, stroke, etc.)
  • Residence in skilled nursing facility
  • Inability to speak, read, or understand English
  • Any safety concerns
  • Participants clinical team excludes the participant from recruitment or evaluation

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
De-implementation InterventionPursed lip breathingThe oxygen de-implementation intervention will consist of: 1) an order to rescind the patient's home oxygen 2) an "unlearning" component targeting provider and patient education and 3) a "substitution" component that introduces alternative evidence-based therapies to treat dyspnea (e.g. teach-to-goal inhaler teaching and pursed lip breathing).
De-implementation InterventionProvider EducationThe oxygen de-implementation intervention will consist of: 1) an order to rescind the patient's home oxygen 2) an "unlearning" component targeting provider and patient education and 3) a "substitution" component that introduces alternative evidence-based therapies to treat dyspnea (e.g. teach-to-goal inhaler teaching and pursed lip breathing).
De-implementation InterventionPatient EducationThe oxygen de-implementation intervention will consist of: 1) an order to rescind the patient's home oxygen 2) an "unlearning" component targeting provider and patient education and 3) a "substitution" component that introduces alternative evidence-based therapies to treat dyspnea (e.g. teach-to-goal inhaler teaching and pursed lip breathing).
De-implementation InterventionTeach-to-goal inhaler trainingThe oxygen de-implementation intervention will consist of: 1) an order to rescind the patient's home oxygen 2) an "unlearning" component targeting provider and patient education and 3) a "substitution" component that introduces alternative evidence-based therapies to treat dyspnea (e.g. teach-to-goal inhaler teaching and pursed lip breathing).
De-implementation InterventionRescind home oxygen orderThe oxygen de-implementation intervention will consist of: 1) an order to rescind the patient's home oxygen 2) an "unlearning" component targeting provider and patient education and 3) a "substitution" component that introduces alternative evidence-based therapies to treat dyspnea (e.g. teach-to-goal inhaler teaching and pursed lip breathing).
Primary Outcome Measures
NameTimeMethod
Discontinuation of Oxygen at 12 weeks12 weeks

The investigators will assess the proportion of participants who have no active prescription for oxygen at 12 weeks.

Secondary Outcome Measures
NameTimeMethod
Proportion of participants completing tele-6MWTAt study completion, an average of 12 weeks

The proportion of participants who are able to complete the tele-6MWT will be calculated.

Post tele-six minute walk test (tele-6MWT) Borg Dyspnea scaleThrough study completion, an average of 12 weeks

The Borg dyspnea scale assesses the difficulty that a patient is having with breathing at the current moment, and ranges from 0 (nothing at all) to 10 (maximal). Within one minute of completing the tele-6MWT, the participant will be asked to grade the severity of their dyspnea based on the modified Borg dyspnea scale.

Cost of interventionAt study completion, an average of 12 weeks

The estimate of costs related to the intervention will be obtained by tracking duration of intervention content and processes. The duration of tasks related to identification and evaluation of subject, enrollment and the intervention will be collected. These tasks will be broken down by level of skill required and a cost estimate calculated.

Clinical COPD Questionnaire (CCQ) Total ScoreThrough study completion, an average of 12 weeks

The disease-specific health status will be measured by the Clinical COPD Questionnaire (CCQ) total Score. The measurement will be defined as the total score of the CCQ at 12 weeks. The CCQ was developed to assess symptoms, functional status, and COPD control and has been used in clinical trials to assess disease specific health status. The measure has strong internal consistency, reliability and validity, and is responsive to change over short time periods. The CCQ consists of 10 items grouped into three domains (symptoms, functional status and mental state), and one total score. Responses range from 0 (never) to 6 (almost all the time). The total score is calculated by adding all the responses and dividing by the total number of items to produce a final score that ranges from 0-6.

Proportion of randomized participants completing 12 week follow upAt study completion, an average of 12 weeks

We will calculate the proportion of randomized patients who complete the 12-week follow-up

Proportion of participants completing in-home spirometryAt study completion, an average of 12 weeks

The proportion of participants who are able to successfully complete in-home spirometry with coaching by study staff will be assessed at the end of the study.

Acceptability to patientsAt study completion, an average of 12 weeks

Among intervention participants, we will perform semi-structured interviews to assess acceptability of the oxygen de-implementation intervention to patients.

Acceptability to providersAt study completion, an average of 12 weeks

Among providers of intervention participants, we will perform semi-structured interviews to assess acceptability of the oxygen de-implementation intervention.

tele-six minute walk test distance (tele-6MWT)Through study completion, an average of 12 weeks

The total distance walked during 6 minutes at the 12 week virtual visit. Participants will be asked to walk for 6 minutes following a premeasured course which was used at the in-person visit and then given to them to take home for the virtual visit.

Proportion of potentially eligible participants randomizedAt study completion, an average of 12 weeks

Proportion of potentially eligible participants that are successfully randomized into the study

Rate of completion of all visitsThrough study completion, an average of 12 weeks

We will assess the rate of completion of all study visits among randomized participants.

Trial Locations

Locations (1)

VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA

🇺🇸

Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath